Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991966 | 0.86 | CYP2D6 (0.59) | POLBALDH1A1DRD2MCHR1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8416135 | 0.84 | CYP2D6 (0.58) | POLBALDH1A1KDM4EDRD2MCHR1 | |
| SCHEMBL24770881 | 0.78 | MMP1 (0.54) | TNIKMMP1MMP9MMP13ADAM17 | |
| SCHEMBL27042826 | 0.78 | MMP1 (0.48) | TNIKMMP1MMP9MMP13ADAM17 | |
| SCHEMBL17163855 | 0.78 | CYP2D6 (0.53) | ALDH1A1DRD2DPP4CYP2D6 | |
| SCHEMBL17082420 | 0.78 | CYP2D6 (0.53) | ALDH1A1DRD2DPP4CYP2D6 | |
| SCHEMBL953425 | 0.78 | CYP2D6 (0.53) | ALDH1A1DRD2DPP4CYP2D6 | |
| SCHEMBL4591580 | 0.77 | ALDH1A1 (0.54) | TNIKMMP1MMP9MMP13ADAM17 | |
| SCHEMBL1427542 | 0.77 | ALDH1A1 (0.58) | TNIKMMP1MMP9MMP13ADAM17 | |
| SCHEMBL32665256 | 0.76 | ALDH1A1 (0.49) | TNIKMMP1MMP9MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296906-A | (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | TNIK 4757/4885MMP1 4859/4885MMP9 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.